Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics has announced the approval of equity awards under its 2021 Inducement Plan, which will grant options to purchase 124,000 shares of the company's common stock to two non-executive employees. The options will vest over a four-year period, with 25% vesting after one year and the remaining 75% vesting quarterly. The awards were made to attract new talent to the company, which is developing gene therapies for inherited retinal diseases and small molecule therapies for other ophthalmic disorders.